Trial · NCT05205330
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety and Tolerability of CR6086 combined with AGEN2034 | From the time of the first dose up to 24 weeks of treatment | Incidence of TEAEs using NCI CTCAE v5.0 |
| Primary | Disease Control rate (DCR) | up to 24 weeks of treatment | Proportion of patients who have achieved CR, PR, or stable disease (SD) per RECIST 1.1 / iRECIST during the Dose Escalation part |
| Primary | Objective Response Rate (ORR) | up to 24 weeks of treatment | Proportion of patients who have achieved CR or PR per RECIST 1.1 / iRECIST during the Expansion part (Phase IIa) |
| Secondary | Disease Control Rate (DCR) | throughout the study | Proportion of patients who have achieved CR, PR, or stable disease (SD) per RECIST 1.1 / iRECIST during the Dose Escalation part |
| Secondary | Objective Response Rate (ORR) | throughout the study | Proportion of patients who have achieved CR or PR per RECIST 1.1 / iRECIST during the Expansion part (Phase IIa) |
| Secondary | Duration Of Response (DOR) | throughout the study, up to 2 years | Time from first documentation of response (CR or PR) until the time of first documentation of disease progression per RECIST 1.1 / iRECIST |
| Secondary | Progression-Free Survival (PFR) | throughout the study, up to 2 years | Time from the first dose of study drugs to the earlier date of assessment of progression per RECIST 1.1 / iRECIST, or death by any cause in the absence of progression |
| Secondary | Progression-Free Survival Rate (PFSR) | throughout the study, up to 2 years | Proportion of patients alive and free of disease progression per RECIST 1.1 / iRECIST at specific timepoints, or death by any cause in the absence of progression |
| Secondary | Overall Survival (OS) | throughout the study, up to 2 years | Time from the first dose of study drugs to the date of death by any cause |
| Secondary | Safety and Tolerability of CR6086 combined with AGEN2034 | throughout the study, up to 2 years | Incidence of TEAEs |
| Other | Evaluate PD-L1 expression by CPS as predictor of response (Main Study/Expansion) | throughout the study |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05205330/registered